Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia

Psychiatric Quarterly

Volumn 84, Issue 1, 2013, Pages 125-135

  Chaves, Katarina Melo ^a   Serrano Blanco, Antoni ^c   Ribeiro, Susana Barbosa ^a   Soares, Luiz Alberto Lira ^a,b   Guerra, Gerlane Coelho Bernardo ^a   Do Socorro Costa Feitosa Alves, Maria ^a   De Araújo Júnior, Raimundo Fernandes ^a   De Paula Soares Rachetti, Vanessa ^a,d   Filgueira Júnior, Antônio ^d   De Araújo, Aurigena Antunes ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c PARC SANITARI SANT JOAN DE DÉU   (Spain)

^d Hospital da Polícia Militar of Rio Grande Do Norte   (Brazil)

Author keywords

Atypical antipsychotic; Quality of life; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEDATIVE AGENT;

ACCOMMODATION; ADULT; AKATHISIA; AKINESIA; AMBULATORY CARE; AMENORRHEA; ARTICLE; ASTHENIA; AUTONOMIC DYSFUNCTION; BRAZIL; CONSTIPATION; CROSS-SECTIONAL STUDY; DEPRESSION; DIARRHEA; DRUG DEPENDENCE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; ERECTILE DYSFUNCTION; ERYTHEMA; FATIGUE; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEART PALPITATION; HUMAN; HYPERKINESIA; HYPOKINESIA; LASSITUDE; LIBIDO; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENORRHAGIA; MENTAL CONCENTRATION; MENTAL DISEASE; MENTAL PATIENT; MICTURITION DISORDER; MUSCLE RIGIDITY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; ORGASM DISORDER; PARESTHESIA; PHOTOSENSITIVITY; POLYDIPSIA; POLYURIA; PRURITUS; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RESTLESSNESS; SALIVATION; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SKIN PIGMENTATION; SLEEP TIME; SOMNOLENCE; TACHYCARDIA; TREATMENT DURATION; TREMOR; VAGINAL DRYNESS; WEIGHT GAIN; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAZIL; CROSS-SECTIONAL STUDIES; DRUG TOXICITY; EMPLOYMENT; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SOCIAL PARTICIPATION;

EID: 84873999099     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-012-9233-3     Document Type: Article

References (27)

1. Philip S: Antipsychotic drugs, dopamine receptors, and schizophrenia. Clinical Neuroscience Research 1(1-2):53-60, 2001
2. Abi-Dargham A, Laruelle M: Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 20(1):15-27, 2005
3. Michalopoulou PG, Shergill SS, Kapur S: New and old antipsychotics: What 'effectiveness' trials tell us. Psychiatry 7(11):443-446, 2008
4. Kao YC, Liu YP, Chou MK, Cheng TH: Subjective quality of life in patients with chronic schizophrenia: Relationships between psychosocial and clinical characteristics. Comprehensive Psychiatry 52(2):171-180, 2011
5. Saarni SI, Pirkola S: Quality of life of psychiatric patients. Duodecim; laaketieteellinen aikakauskirja 126(19):2265-2273, 2010
6. Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L: Schizophrenia and quality of life: How important are symptoms and functioning? International Journal of Mental Health Systems 4:31, 2010
7. Heinrichs DW, Hanlon TE, Carpenter WT: The quality of life scale - an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10(3):388-398, 1984
8. Ueoka Y, Tomotake M, Tanaka T, Kaneda Y, Taniguchi K, Nakataki M, et al.: Quality of life and cognitive dysfunction in people with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 35(1):53-59, 2011
9. Song YY, Kim KR, Park JY, Lee SY, Kang JI, Lee E, et al.: Associated factors of quality of life in first-episode schizophrenia patients. Psychiatry Investigation 8(3):201-206, 2011
10. Cardoso CS, Bandeira M, Caiaffa WT, Fonseca JOP: Escala de qualidade de vida para pacientes com esquizofrenia QLS-BR: Adaptação transcultural para o Brasil. Jornal Brasileiro de Psiquiatria 51(1):31-38, 2002
11. Brasil MdSd: Aprova o componente especializado da assistência farmacêutica. Diario Oficial Uniao, p. 725, 2009
12. Manual Diagnóstico e Estatístico de Transtornos Mentais - DSM-IV-TR-TM: ArtMed Porto Alegre, 2003
13. Brasil Mdsd: Protocolo clínico e diretrizes terapêuticas - esquizofrenia refratária. In: CONASS (Ed) Brasília, 2002
14. Human D: Declaration of Helsinki. Lancet 357(9251):236, 2001
15. Garcia-Navarro A, Gonzalez-Puga C, Escames G, Lopez LC, Lopez A, Lopez-Cantarero M, et al.: Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. Journal of Pineal Research 43(2):195-205, 2007
16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334:1-100, 1987
17. Carpiniello B, Mellino G, Pintore S, Puddu L, Pinna F: Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study. Clinica Terapeutica 162(4):331-341, 2011
18. Cianchetti C, Ledda MG: Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. Psychiatric Research 189(3):349-356, 2011
19. Foussias G, Remington G: Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Canadian Journal Of Psychiatry Revue Canadienne de Psychiatrie 55(3):117-125, 2010
20. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al.: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry 168(9):947-956, 2011
21. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y: Quality of life outcomes of risperidone olanzapine and typical antipsychotics among schizophrenia patients treated in routine clinical practice - a naturalistic comparative study. Journal of Clinical Psychopharmacology 24(6):582-591, 2004
22. Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D: The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Journal of Clinical Psychiatry 67(9):1397-1403, 2006
23. Leão A, Barros S: As representações sociais dos profissionais de saúde mental acerca do modelo de atenção e as possibilidades de inclusão social. Saúde e Sociedade 17:95-106, 2008
24. Kim YT, Kang BJ: A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. Human Psychopharmacology: Clinical and Experimental 19(4):265-269, 2004
25. Haddad PM, Hellewell JSE, Wieck A: Antipsychotic induced hyperprolactinaemia: A series of illustrative case reports. Journal of Psychopharmacology 15(4):293-295, 2001
26. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al.: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 164(3):415-427, 2007
27. Ciudad A, Alvarez E, Bousono M, Olivares JM, Gomez JC: Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms. Actas Españolas de Psiquiatría 35(2):105-114, 2007